Madison Roberts

But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules designed to promote neuroplasticity without psychoactive effects. This path represents a major leap forward in making psychedelic-like benefits practical, scalable, and clinically accessible.

AbbVie’s quiet acquisition of Gilgamesh Pharmaceuticals, reportedly worth close to $1 billion, did more than make headlines. It signaled something far more significant: Big Pharma has officially entered the psychedelic-adjacent chat.For years, mental health innovators have been working on a new class of therapies, compounds that mimic the neuroplasticity-promoting effects of psychedelics without the hallucinogenic experience. These molecules, often labeled “non-hallucinogenic psychoplastogens” or “neuroplastogens,” were largely considered too early, too experimental, or too fringe to attract serious acquisition interest. Until now.With one deal, AbbVie reshaped the M&A landscape. And now, investors and pharma scouts alike are asking the same question: who’s next?

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being tested, as Gilgamesh Pharmaceuticals moves to challenge Enveric’s patent claims, just weeks after AbbVie announced its $1.2 billion acquisition of Gilgamesh’s lead compound, Bretisilocin (GM-2505).

Nursing students from Falmouth recently celebrated ahead of their clinical experience at the annual Blessing of the Hands ceremonies at St. Anselm College and Emmanuel College.